DeepMed Research

UNIVERSITY OF SOUTHERN CALIFORNIA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1880-01-01

Employees: 10K

Market Cap: -

Website: http://startusc.com

Clinical Trials

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Therapy-Related Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Pevonedistat
Other: Pharmacological Study

First Posted Date: 2017-11-06

Last Posted Date: 2024-01-09

Lead Sponsor: University of Southern California

Target Recruit Count: 53

Registration Number: NCT03330821

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 2 locations

A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff

Not Applicable

Completed

Conditions: Deep Vein Thrombosis
Venous Thrombosis

Interventions: Device: Deep Vein Thrombosis (DVT) Cuff

First Posted Date: 2017-11-01

Last Posted Date: 2019-09-06

Lead Sponsor: University of Southern California

Target Recruit Count: 36

Registration Number: NCT03328624

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

High Dose Bupropion for Smoking Cessation - Pilot Study

Phase 2

Terminated

Conditions: Smoking (Tobacco) Addiction
Smoking Cessation
Smoking, Tobacco
Cessation, Tobacco
Cigarette Smoking

Interventions: Drug: Bupropion Hydrochloride

First Posted Date: 2017-10-31

Last Posted Date: 2023-07-17

Lead Sponsor: University of Southern California

Target Recruit Count: 12

Registration Number: NCT03326128

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Genetics of Beta Cell Failure in Mexican Americans

Completed

Conditions: Gestational Diabetes
Physical Activity
Adipokines
Air Pollution
Genetics
Nutrition
Insulin Resistance
Obesity
Diabetes Type 2
Beta Cell Function

First Posted Date: 2017-10-04

Last Posted Date: 2023-11-18

Lead Sponsor: University of Southern California

Target Recruit Count: 1250

Registration Number: NCT03301519

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Phase 3

Terminated

Conditions: Colorectal Adenocarcinoma
Stage IIIB Colorectal Cancer AJCC v7
Stage IIIC Colorectal Cancer AJCC v7
Stage III Colorectal Cancer AJCC v7
RAS Wild Type
Stage IIIA Colorectal Cancer AJCC v7
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions: Biological: Panitumumab
Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Other: Quality-of-Life Assessment
Drug: Capecitabine
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-03

Last Posted Date: 2020-06-11

Lead Sponsor: University of Southern California

Target Recruit Count: 4

Registration Number: NCT03300609

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Not Applicable

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Perflutren Lipid Microspheres
Drug: Sulfur Hexafluoride Lipid Microspheres
Device: Dynamic Contrast-Enhanced Ultrasound Imaging
Device: Positron Emission Tomography
Device: Computed Tomography
Biological: Yttrium-90 (90Y)

First Posted Date: 2017-10-03

Last Posted Date: 2019-05-16

Lead Sponsor: University of Southern California

Registration Number: NCT03300401

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Addressing Uncontrolled Diabetes in Primary Care: A Lifestyle Redesign Approach

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Behavioral: Lifestyle Redesign

First Posted Date: 2017-09-26

Last Posted Date: 2020-03-24

Lead Sponsor: University of Southern California

Target Recruit Count: 143

Registration Number: NCT03293914

Locations: 🇺🇸
LAC+USC Primary Care Adult West Clinic, Los Angeles, California, United States

Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors

Not Applicable

Terminated

Conditions: Cancer Survivor
No Evidence of Disease
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Obesity
Overweight
Stage IIIC Breast Cancer
Sedentary Lifestyle
Stage I Breast Cancer
Stage IB Breast Cancer

Interventions: Behavioral: Exercise Intervention
Other: Laboratory Biomarker Analysis
Device: Monitoring Device
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-09-15

Last Posted Date: 2020-05-12

Lead Sponsor: University of Southern California

Target Recruit Count: 23

Registration Number: NCT03284346

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty

Conditions: Pulmonary Embolism

First Posted Date: 2017-09-07

Last Posted Date: 2023-11-18

Lead Sponsor: University of Southern California

Target Recruit Count: 100

Registration Number: NCT03275610

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Phase 2

Terminated

Conditions: Cervical Squamous Cell Carcinoma In Situ
Vulvar High Grade Squamous Intraepithelial Lesion

Interventions: Drug: Cyclophosphamide
Drug: Indomethacin
Biological: IRX-2
Other: Laboratory Biomarker Analysis
Dietary Supplement: Multivitamin
Other: Placebo
Drug: Omeprazole
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-08-30

Last Posted Date: 2025-04-13

Lead Sponsor: University of Southern California

Target Recruit Count: 10

Registration Number: NCT03267680

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy